Efficacy of Homeopathic Nasal Formulation for Management of Experimental Rhinoviral Colds

This study has been completed.
Sponsor:
Collaborator:
Procter and Gamble
Information provided by:
University of Wisconsin, Madison
ClinicalTrials.gov Identifier:
NCT00358774
First received: July 28, 2006
Last updated: October 31, 2008
Last verified: October 2008

July 28, 2006
October 31, 2008
March 2001
March 2002   (final data collection date for primary outcome measure)
The proportion of subjects who become infected and show the presence of a cold.(active vs placebo)
Same as current
Complete list of historical versions of study NCT00358774 on ClinicalTrials.gov Archive Site
  • The proportion of subjects who become infected.
  • The mean number of days that virus was shed for inoculated subjects (active vs placebo)
Same as current
Not Provided
Not Provided
 
Efficacy of Homeopathic Nasal Formulation for Management of Experimental Rhinoviral Colds
A Double-Blind, Placebo-Controlled Trial to Test the Efficacy of Homeopathic Nasal Formulation for the Management of Experimental Rhinoviral Colds in an Outpatient Setting

Common colds affect many people and are the cause of bothersome symptoms such as runny or stuffy nose, sore throat, headache and sneezing. Common colds can also cause more severe illnesses in certain groups of people like the elderly, people with chronic lung diseases such as asthma.

This study is designed to test whether a non-drug (homeopathic) nasal spray will reduce the incidence of colds, decrease cold related symptoms or shorten the length of the cold.

Common colds are the most frequent type of respiratory infection, and although the clinical manifestations are usually not life threatening or debilitating, they cause annoying symptoms such as nasal congestion, rhinorrhea, malaise, sore throat and sneezing, that can interfere with activities of daily living. Furthermore, colds can cause more severe illnesses in certain people including: infants, the elderly, and people with asthma, chronic lung diseases, or immune deficiency.

This clinical trial is designed to test whether a new homeopathic formulation has beneficial effects on the management of common colds that have been induced by inoculation of rhinovirus into the nose of healthy subjects.

The objective of this research clinical study is to evaluate the effectiveness of a homeopathic nasal formulation for the management of experimentally-induced common colds as indicated by a reduction in:

  • Cold incidence compared to placebo,
  • Symptom severity compared to placebo
  • Cold duration compared to placebo
  • Infection rate compared to placebo
  • Duration of virus shedding compared to placebo or
  • Amount of virus shedding compared to placebo
Interventional
Phase 1
Phase 2
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double-Blind
Primary Purpose: Prevention
Common Cold
Procedure: homeopathic nasal spray
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
40
March 2002
March 2002   (final data collection date for primary outcome measure)

Inclusion Criteria:

To be considered eligible for enrollment into this study, subject must:

  1. Be healthy based on medical history, physical and nasal examination
  2. Be male or non-pregnant, non-lactating female (women of child-bearing potential must be using an acceptable form of contraception, including abstinence, as determined by the Investigator)
  3. Be between 18 - 60 years old
  4. Be willing to refrain from taking nasal decongestants, antihistamines or cough/cold preparations (this includes dietary supplements and homeopathic preparations used specifically for cold/flu e.g., vitamin C, zinc, echinacea) within the 7 days prior to Day 0 and through Day 5
  5. Be willing to refrain from taking any other medication (except contraceptive preparations, hormone replacement therapy, acne medication) within 2 days prior to Day 0 and through Day 5
  6. Has read, signed and received a copy of the Informed Consent Form.

Exclusion Criteria:

Subjects will be excluded from the study if they:

  1. Are intolerant of nasal sprays
  2. Require a medication on regular basis (3 or more times/week) except contraceptive preparations, hormone replacement therapy, acne medication
  3. Have a history of chronic diseases such as respiratory (e.g., chronic rhinitis, sinusitis, asthma, chronic bronchitis, pneumonia, persistent or chronic cough, emphysema, breathing problems, excessive phlegm or mucus), cardiovascular, endocrine, neurological, hepatic, gastrointestinal, renal, hematological, urological, immunological, ophthalmic diseases requiring medication
  4. Have a history of headache (e.g., frequent migraines, cluster headaches, 3+ headaches/week)
  5. Have had cold symptoms in the past 14 days
  6. Are currently symptomatic with respiratory allergy
  7. Have any clinically significant abnormalities of the upper (including history of nose bleeds, nasal abnormalities or other nasal pathology such as irreversible nasal mucosal hypertrophy or severe nasal septal deviation) or lower respiratory tract
  8. Have used any investigational medication in the past 30 days
  9. Are smokers
  10. Have serum neutralizing antibody titer of >1 to RV16 at Pre-screening
  11. Have a condition or is taking a medication that the Investigator and/or designee believes could jeopardize the safety of the subject, would interfere with the evaluation or confound the interpretation of the study results
  12. Have positive urine pregnancy test (for female subjects only)
Both
18 Years to 60 Years
Yes
Contact information is only displayed when the study is recruiting subjects
Not Provided
 
NCT00358774
200148
Not Provided
Not Provided
University of Wisconsin, Madison
Procter and Gamble
Principal Investigator: James E Gern, MD University of Wisconsin, Madison
University of Wisconsin, Madison
October 2008

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP